Talphera Q1 net loss narrows as costs rise on higher development spending

Talphera

13/05/2026 21:18

Overview

US specialty pharma firm reported no Q1 revenue, unchanged from minimal revenue a year ago

Net loss for Q1 narrowed slightly yr/yr as R&D and SG&A expenses rose

Company expects NEPHRO CRRT clinical study to complete enrollment in 2026

Outlook

Company expects NEPHRO CRRT clinical study to be completed in 2026

Talphera says clinical study sites remain focused on enrollment and study quality

Company believes nafamostat could address unmet need in CRRT anticoagulants if approved

Result Drivers

HIGHER DEVELOPMENT EXPENSES - Co said increased R&D and SG&A expenses in Q1 were mainly due to higher Niyad development costs as NEPHRO CRRT study enrollment rose

CLINICAL TRIAL PROGRESS - Co reported surpassing 50% enrollment in NEPHRO CRRT study, with completion expected in 2026

FINANCING MILESTONE - Co closed $4.1 mln tranche of private placement financing after reaching 35-patient enrollment milestone in NEPHRO CRRT study

Company press release: ID:nPnccTvcRa

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Net Income
Beat
-$2.56 mln
-$3.73 mln (1 Analyst)
Q1 Income From Operations
Miss
-$3.95 mln
-$3.73 mln (1 Analyst)
Q1 Net Income From Cont Ops
-$2.56 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Talphera Inc is $3.25, about 279% above its May 12 closing price of $0.86

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)